Literature DB >> 25483496

Licensed pertussis vaccines in the United States. History and current state.

Nicola P Klein1.   

Abstract

The United States switched from whole cell to acellular pertussis vaccines in the 1990s following global concerns with the safety of the whole cell vaccines. Despite high levels of acellular pertussis vaccine coverage, the United States and other countries are experiencing large pertussis outbreaks. The aim of this article is to describe the historical context which led to acellular pertussis vaccine development, focusing on vaccines currently licensed in the US, and to review evidence that waning protection following licensed acellular pertussis vaccines have been significant factors in the widespread reappearance of pertussis.

Keywords:  acellular; history; pertussis; protection; vaccines; waning

Mesh：

Substances：

Year:  2014        PMID： 25483496      PMCID： PMC4975064          DOI： 10.4161/hv.29576

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  69 in total

1.  Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010.

Authors:  Sophie Octavia; Vitali Sintchenko; Gwendolyn L Gilbert; Andrew Lawrence; Anthony D Keil; Geoff Hogg; Ruiting Lan
Journal:  J Infect Dis       Date:  2012-03-13       Impact factor: 5.226

Review 2.  Duration of immunity against pertussis after natural infection or vaccination.

Authors:  Aaron M Wendelboe; Annelies Van Rie; Stefania Salmaso; Janet A Englund
Journal:  Pediatr Infect Dis J       Date:  2005-05       Impact factor: 2.129

3.  The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada.

Authors:  Julie A Bettinger; Scott A Halperin; Gaston De Serres; David W Scheifele; Theresa Tam
Journal:  Pediatr Infect Dis J       Date:  2007-01       Impact factor: 2.129

4.  Waning protection after fifth dose of acellular pertussis vaccine in children.

Authors:  Nicola P Klein; Joan Bartlett; Ali Rowhani-Rahbar; Bruce Fireman; Roger Baxter
Journal:  N Engl J Med       Date:  2012-09-13       Impact factor: 91.245

5.  Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.

Authors:  Lennart Gustafsson; Luc Hessel; Jann Storsaeter; Patrick Olin
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

6.  The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children.

Authors:  C D Christie; M L Marx; C D Marchant; S F Reising
Journal:  N Engl J Med       Date:  1994-07-07       Impact factor: 91.245

7.  Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1992-10-09

8.  Pertussis--United States, January 1992-June 1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-07-21       Impact factor: 17.586

9.  Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Karen R Broder; Margaret M Cortese; John K Iskander; Katrina Kretsinger; Barbara A Slade; Kristin H Brown; Christina M Mijalski; Tejpratap Tiwari; Emily J Weston; Amanda C Cohn; Pamela U Srivastava; John S Moran; Benjamin Schwartz; Trudy V Murphy
Journal:  MMWR Recomm Rep       Date:  2006-03-24

10.  Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-02-22       Impact factor: 17.586
View more
  30 in total

Review 1.  Strategies and new developments to control pertussis, an actual health problem.

Authors:  María Emilia Gaillard; Daniela Bottero; Griselda Moreno; Martin Rumbo; Daniela Hozbor
Journal:  Pathog Dis       Date:  2015-08-09       Impact factor: 3.166

Review 2.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

Review 3.  Bordetella pertussis: new concepts in pathogenesis and treatment.

Authors:  Nicholas H Carbonetti
Journal:  Curr Opin Infect Dis       Date:  2016-06       Impact factor: 4.915

4.  Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.

Authors:  Xin-Xing Gu; Stanley A Plotkin; Kathryn M Edwards; Alessandro Sette; Kingston H G Mills; Ofer Levy; Andrea J Sant; Annie Mo; William Alexander; Kristina T Lu; Christopher E Taylor
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

Review 5.  Contribution of pertussis toxin to the pathogenesis of pertussis disease.

Authors:  Nicholas H Carbonetti
Journal:  Pathog Dis       Date:  2015-09-21       Impact factor: 3.166

6.  Acellular Pertussis Vaccine Effectiveness Over Time.

Authors:  Ousseny Zerbo; Joan Bartlett; Kristin Goddard; Bruce Fireman; Edwin Lewis; Nicola P Klein
Journal:  Pediatrics       Date:  2019-06-10       Impact factor: 7.124

7.  Toward a Controlled Human Infection Model of Pertussis.

Authors:  Tod J Merkel
Journal:  Clin Infect Dis       Date:  2020-07-11       Impact factor: 9.079

Review 8.  What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Authors:  Nicolas Burdin; Lori Kestenbaum Handy; Stanley A Plotkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

Review 9.  Pertussis vaccines and protective immunity.

Authors:  Parul Kapil; Tod J Merkel
Journal:  Curr Opin Immunol       Date:  2019-05-09       Impact factor: 7.486

10.  Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development.

Authors:  Nicholas H Carbonetti; Carl Heinz Wirsing von König; Ruiting Lan; Francoise Jacob-Dubuisson; Peggy A Cotter; Rajendar Deora; Tod J Merkel; Cécile A van Els; Camille Locht; Daniela Hozbor; Maria E Rodriguez
Journal:  Clin Vaccine Immunol       Date:  2016-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.